07 Sep Court sanction of the Scheme of Arrangement
Paris, France and Eastleigh, UK – 7 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today’s announcement by Yourgene Health plc (“Yourgene”), in relation to the recommended cash offer made by Novacyt UK Holdings Limited (“Novacyt UK”), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the “Acquisition”), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”). A circular in relation to the Scheme was published by Yourgene on 27 July 2023 (the “Scheme Document”).
Capitalised terms used in this announcement shall, unless otherwise defined, have the same meaning as set out in the Scheme Document.
Further to the announcement made by Yourgene on 17 August 2023 in relation to the passing of the Resolutions required to approve and implement the Scheme at the Court Meeting and the General Meeting, Yourgene has announced that at the Court Sanction Hearing held earlier today the Court issued the Court Order sanctioning the Scheme.
There has been no change to the expected timetable of principal events for the Acquisition set out in the Scheme Document.